期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

乳腺癌内科治疗的现状及展望 被引量：5

Current status and prospect of breast cancer treatment
下载PDF
导出
摘要 本文对近年来可手术乳腺癌辅助治疗以及晚期转移性乳腺癌的内科治疗进展进行了回顾,认为规范化、个体化和靶向治疗是乳腺癌的治疗方向。 Recent data of adjuvant therapy in operable breast cancer and chemotherapy or endocrine therapy in advanced breast cancer were reviewed in this article. The standardization, individualization and target therapy may be the direction of breast cancer treatment.
作者 徐兵河
机构地区 中国医学科学院中国协和医科大学肿瘤医院肿瘤研究所内科
出处 《癌症进展》 2004年第1期5-10,17,共7页 Oncology Progress
关键词 乳腺癌 辅助治疗 内分泌治疗 化疗 breast cancer adjuvant therapy chemotherapy endocrine therapy
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献17

  • 1[1]Fisher B,Brown AM,Dimitrov NV,et al.Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide,methotrxate,and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors:Results from the National Surgical Adjuvant Breast and Bowel Project B-15.J Clin Oncol,1990,8:1483
  • 2[2]Early Breast Cancer Trialists' Collaborative Group.Polychemotherapy for early breast cancer:An overview of the randomized trials.Lancet,1998,352:930
  • 3[3]Hutchins L,Green S,Ravdin P,et al.CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients:First results of intergroup trial in 0102.Proc Am Soc Clin Oncol,1998,17:Abst 2
  • 4[4]Henderson IC,Berry D,Demetri GD,et al.Improved outcomes from adding sequential paclitaxel but not from eslating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.J Clin Oncol,2003,21(6):976
  • 5[5]Martin M,Pienkowski T,Mackey J,et al.TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients,BCIRG 001:55 months follow-up.Breast Cancer Res Treat,2003,82(Suppl 1):Abstr 43
  • 6[6]Fisher B,Dignam J,Bryant J,et al.Five versus more than five years of tamoxifen for lymph node-negative breast cancer:Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial.J Natl Cancer Inst,2001,93:684
  • 7[7]Albain KS,Green SJ,Racsin PM,et al.Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent:Initial results from intergroup trial 0100(SWOG-8814).Proc AmSoc Clin Oncol,2002,21:37
  • 8[8]Dowsett M.Analysis of time to recurrence in the ATAC(arimidex,tamoxifen,alone or in combination)trial according to estrogen receptor and progesterone receptor status.Breast Cancer Res Treat,2003,82(Suppl 1):Abstr 4
  • 9[9]Goss PE,Ingle JN,Martino S,et al.Randomized placebo-controlled trial of letrozole in postmenopausal women with early breast cancer completing five years of tamoxifen.Breast Cancer Res Treat,2003,82(Suppl 1 ):Abstr 42
  • 10[10]Citro ML,Berry DA,Cirrincione C,et al.Randomized trial of dose-dense versus conventionally schedule and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of nodepositive primary breast cancer:First report of intergroup trial C9741/Cancer and Leukemia Group B trial 9741.J Clin Oncol,2003,21(7):1431

同被引文献27

引证文献5

二级引证文献21

癌症进展
2004年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部